Summary
Biogen Inc. (BIIB) filed an 8-K on August 26, 2013, to disclose the amendment of its CEO George A. Scangos's employment agreement. The amendment extends his employment term to July 15, 2014, with automatic twelve-month extensions thereafter, signaling continued leadership and stability at the executive level. His base salary remains $1,375,000 with a target bonus of at least 140% of his base salary, and he will continue to be eligible for equity incentives. These terms indicate the company's commitment to retaining its CEO and aligning his compensation with performance and long-term company success.
Key Highlights
- 1CEO George A. Scangos's employment agreement has been amended and extended.
- 2The amended agreement supersedes the previous agreement dated June 28, 2010.
- 3Dr. Scangos's employment term is extended to July 15, 2014, with subsequent automatic twelve-month renewals.
- 4His annual base salary of $1,375,000 remains in place, subject to adjustments.
- 5Dr. Scangos has a target bonus opportunity of no less than 140% of his base salary.
- 6He will continue to be eligible for long-term and equity incentive plans.
- 7The agreement outlines specific provisions for vesting and exercise of outstanding awards upon termination without cause, voluntary termination under certain circumstances, death, or disability.
Frequently Asked Questions
This 8-K filing announces the amendment and extension of the employment agreement for Biogen's CEO, George A. Scangos, Ph.D., ensuring continued leadership and clarifying executive compensation and severance terms.
Dr. Scangos's base salary remains $1,375,000 annually, with a target bonus opportunity of at least 140% of his base salary. He will also continue to be eligible for equity incentives under the company's plans.
The primary change relates to the treatment of outstanding equity awards upon termination. The amended agreement clarifies that upon termination without cause, voluntary termination under specific conditions, death, or disability, Dr. Scangos's outstanding long-term incentive awards will continue to vest or vest fully, with extended exercise periods in certain scenarios, aligning with typical executive retention and severance practices.
Yes, the amended employment agreement extends Dr. Scangos's employment term until July 15, 2014, with provisions for automatic annual extensions thereafter, indicating the company's intention to retain his leadership beyond the initial term.